Skip to main content
芭薇股份 logo

芭薇股份 — Investor Relations & Filings

Ticker · 920123 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 240 across all filing types
Latest filing 2026-04-26 Audit Report / Informat…
Country CN China
Listing Beijing Stock Exchange 920123

About 芭薇股份

https://www.gzbawei.com/

Guangdong Bawei Biotechnology Corp., Ltd. is a comprehensive beauty and personal care solution provider specializing in research, development, production, and testing. The company offers integrated OEM, ODM, and OBM services, covering a wide range of product categories including skincare, hair care, body care, and makeup. Bawei is recognized for its commitment to scientific innovation, operating advanced R&D laboratories and an independent third-party testing center that ensures product safety and efficacy. By leveraging automated production lines and a rigorous quality management system, the company serves a diverse portfolio of domestic and international brands. Its core focus remains on delivering high-quality, customized formulations and manufacturing excellence to meet evolving consumer demands in the global beauty market.

Recent filings

Filing Released Lang Actions
董事会审计委员会对会计师事务所履行监督职责情况报告
Audit Report / Information Classification · 95% confidence The document is a report from the Board Audit Committee regarding the supervision of the accounting firm for the fiscal year 2025. It details the evaluation of the auditor's qualifications, audit process oversight, and overall assessment of the auditor's performance. It does not contain the full audit report or financial statements but focuses on the audit committee's supervisory role and evaluation of the auditor's work. The document length is short (1296 characters) and is a formal report on audit supervision, which fits the category of Audit Report / Information (AR) rather than a full Annual Report or other filings. Therefore, the appropriate classification is AR with high confidence. FY 2025
2026-04-26 Chinese
万联证券股份有限公司关于广东芭薇生物科技股份有限公司2025年年度募集资金存放、管理与实际使用情况专项核查报告
Audit Report / Information Classification · 95% confidence The document is a detailed report from Wanlian Securities regarding the 2025 annual status of the fundraising funds of Guangdong Bawei Biotechnology Co., Ltd. It includes specifics on the amount raised, usage, management, and compliance with regulatory requirements. The document references regulatory approvals, fundraising amounts, usage breakdowns, and compliance with fundraising management rules. It is a specialized audit and verification report on the use and management of funds raised through a public stock issuance. The document is not an annual report, earnings release, or general regulatory filing but a focused audit-type report on fundraising funds usage and management. This matches the definition of an Audit Report / Information (AR) which covers standalone audit reports and applied accounting principles related to specific regulatory requirements, excluding full annual reports. The document length (6261 characters) and detailed financial data support it being a substantive report rather than a brief announcement or certification. Therefore, the correct classification is AR with high confidence. FY 2025
2026-04-26 Chinese
第四届董事会第十次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 10th meeting of the 4th Board of Directors of Guangdong Bawei Biotechnology Co., Ltd. It includes multiple agenda items such as approval of the 2025 annual report, financial statements, management reports, remuneration plans, audit reports, ESG report, and other governance-related documents. The document repeatedly states that the detailed reports are disclosed separately on the designated information disclosure platform and that these resolutions are submitted for shareholder approval where necessary. The document is not the reports themselves but a formal announcement of the board meeting decisions and approvals. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board. The document length (7637 characters) and content confirm it is not a full annual report or financial report but a board meeting resolution announcement.
2026-04-26 Chinese
董事、高级管理人员薪酬管理制度
Remuneration Information Classification · 95% confidence The document is titled '董事、高级管理人员薪酬管理制度' which translates to 'Remuneration Management System for Directors and Senior Management'. It details the company's policies, principles, and procedures regarding the compensation of directors and senior executives. The content includes salary structure, performance evaluation, payment, adjustments, and related governance. There is no indication that this is an announcement of a report or a certification. It is a detailed report on remuneration policies, fitting the definition of a Remuneration Information filing. The document length is 2839 characters, which is relatively short but the content is substantive and specific to remuneration policies, not a mere announcement or summary. Therefore, the appropriate classification is 'DEF 14A' for Remuneration Information.
2026-04-26 Chinese
董事会审计委员会2025年度履职情况报告
Audit Report / Information Classification · 95% confidence The document is titled as a "Board Audit Committee 2025 Annual Performance Report" from Guangdong Bawei Biotechnology Co., Ltd. It details the audit committee's composition, meetings held in 2025, oversight of external auditors, internal audit guidance, and evaluation of internal controls. The content focuses on the audit committee's activities and oversight rather than presenting full financial statements or audit opinions alone. The document length is 2064 characters, which is relatively short and more of a committee report rather than a full audit report or annual report. It is not a certification or a brief announcement but a detailed report on the audit committee's performance and activities for the year 2025. This fits best under the category of Audit Report / Information (AR), which includes reports on audit committee activities and audit-related oversight, distinct from full annual reports or standalone audit opinions. FY 2025
2026-04-26 Chinese
关于计提资产减值准备的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the company's decision to make asset impairment provisions based on accounting standards and board resolutions. It details the impairment losses recognized for the fiscal year ending December 31, 2025, and includes board and audit committee approvals. The document is relatively short (1464 characters) and serves as a formal announcement of a specific accounting action rather than a full financial report or audit report. It does not contain comprehensive financial statements or detailed audit opinions but rather a summary of impairment provisions and related board decisions. Therefore, it fits best under Regulatory Filings (RNS) as a formal regulatory announcement that does not qualify as a full Annual Report, Audit Report, or Interim Report.
2026-04-26 Chinese

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.